Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: #Breeze who wrote (18594)	12/17/2024 9:52:45 AM
From: Kirk ©	Read Replies (1) \| Respond to of 26384

I just missed adding to PFE at the April low... Will we get another chance? Message #18594 from #Breeze at 4/15/2024 8:20:36 PM PFE Wave Count Update. Assume Wave 3 is complete. tradingview.com Pfizer issues 2025 outlook, reiterates 2024 guidance Dec. 17, 2024 7:05 AM ET Pfizer Inc. (PFE) Stock By: Dulan Lokuwithana, SA News Editor Pfizer (NYSE: PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant issued its full-year 2025 guidance and reaffirmed its full-year 2024 outlook in line with Street forecasts. The company expects its full-year 2025 revenues and adjusted diluted earnings per share to reach $61.0B-$64.0B and $2.80-$3.00, respectively, compared to $63.28B and $2.88 in the consensus. Its unchanged 2024 outlook for revenue and adjusted diluted EPS stand at $61.0B–$64.0B and $2.75–$2.95 compared to $62.88B and $2.93 projected by analysts, respectively. Its 2025 revenue outlook includes about $1B net unfavorable impact related to the Medicare Part D Redesign changes, specifically the $2,000 annual out-of-pocket cap required from the 2022 Inflation Reduction Act (IRA). The COVID-19 vaccine maker said it has realized $4B in net cost savings through 2024 and intends to achieve $500M in additional savings next year through the ongoing cost realignment program. Pfizer (NYSE: PFE) will hold an analyst webcast on Tuesday at 8:30 a.m. EST to provide additional commentary.